Archives of Dermatological Research最新文献

Chronic spontaneous urticaria (CSU) is a distressing skin disorder characterized by recurrent wheals, angioedema, and persistent itching lasting more than 6 weeks. Remibrutinib, a selective oral Bruton’s tyrosine kinase (BTK) inhibitor, has shown potential as a novel therapy for patients who remain symptomatic despite standard antihistamine treatment. This study aimed to evaluate the efficacy and safety of remibrutinib. A comprehensive search was conducted across PubMed, Scopus, Web of Science, Cochrane CENTRAL, and ClinicalTrials.gov up to March 2025. Primary outcomes included changes in the weekly Urticaria Activity Score (UAS7), the proportion of patients achieving low disease activity (UAS7 ≤ 6) or complete symptom resolution (UAS7 = 0), and Dermatology Life Quality Index (DLQI) scores. Safety outcomes were assessed by evaluating adverse events, serious adverse events, and treatment discontinuations. Subgroup analyses explored the effects of different remibrutinib doses. Three RCTs involving 1,236 patients met the inclusion criteria. Remibrutinib 25 mg twice daily significantly reduced UAS7 scores compared to placebo by week 2 (mean difference [MD] = − 11.50; 95% CI − 14.23 to − 8.77; P < 0.00001), with sustained improvement at week 12 (MD = − 7.82; 95% CI − 10.31 to − 5.33; P < 0.00001) and week 24 (MD = − 5.66; 95% CI − 7.62 to − 3.70; P < 0.00001). More patients achieved low disease activity or complete resolution with remibrutinib, and DLQI scores improved accordingly. The safety profile of remibrutinib was comparable to placebo, with no significant differences in serious adverse events, overall adverse events, or discontinuations. These findings support remibrutinib 25 mg twice daily as an effective and well-tolerated oral treatment for antihistamine-refractory CSU. Its rapid onset, sustained benefit, and favorable safety profile make it a strong candidate for inclusion in future CSU treatment guidelines.

Microneedles (MNs) represent a groundbreaking technology for minimally invasive, transdermal delivery of therapeutic and diagnostic agents. Inspired by natural structures such as snake fangs, mosquito proboscises, honeybee stingers, and octopus’ suckers, bioinspired MNs have evolved to overcome limitations of conventional drug delivery systems. This review comprehensively explores the design principles, material innovations, and applications of bioinspired MNs, with a special focus on their fabrication using advanced 3D and 4D printing technologies. These smart microneedles exhibit exceptional mechanical strength, enhanced tissue adhesion, and stimuli-responsive behaviour, making them ideal for chronic disease management, wound healing, biosensing, and personalized medicine. Furthermore, the review highlights emerging strategies in adaptive microneedle design, including shape-morphing capabilities and targeted delivery enabled by environmental triggers such as pH, temperature, glucose, and reactive oxygen species. Overall, the integration of bioinspired design with additive manufacturing platforms paves the way for next-generation MNs systems with translational potential in clinical and biomedical settings.

Graphical abstract

Hair loss is a prevalent disorder negatively affecting the quality of life and mental health. However, current treatment options are limited, highlighting the urgent need for the development of new therapies. Growing evidence has proven that stem cell-derived nutrient medium and exosome are novel approaches to future hair loss therapy. Limelight (CB-EVs) is an umbilical cord blood-derived exosome product. This study was to investigate the safety and efficacy of Limelight (CB-EVs) for hair growth ex vivo. Our analysis revealed that concentrations of Limelight (CB-EVs) below 5 U/ml demonstrated no cytotoxicity in vitro through MTS assay. In hair follicle culture, concentrations of 0.1, 0.01, and 0.001 U/ml significantly promoted hair elongation while maintaining hair bulb diameter. Analysis of the hair growth cycle indicated a reduced transition from the anagen phase to the catagen phase. Overexpression of Laminin V and Collagen XVII were seen by immunohistochemistry staining. These results endorse the exosome product, Limelight (CB-EVs), offers a safe and effective method for stimulating hair growth ex vivo.

Psychodermatology explores the complex, bidirectional relationship between dermatologic conditions and mental health. This review details the primary categories of psychodermatologic disorders, explores how social determinants shape access, adherence, and outcomes, and highlights the need for reform in medical training and cross-disciplinary collaboration to advance patient care and promote health equity.

Dermatologic procedures commonly provoke anxiety, stress, and pain, which can influence overall patient satisfaction. Traditional pain management often targets physical discomfort while overlooking the psychological aspects of these experiences. Virtual reality (VR), an emerging immersive tool in healthcare, may help address both components by reducing anxiety and improving the patient experience. This scoping review examined the potential role of VR in dermatologic procedures for both adults and children. A search of PubMed, EBSCO, OvidMEDLINE, PsycINFO, and the Cochrane Library identified 205 articles, of which 8 met inclusion criteria. Across these studies, VR consistently reduced anxiety and was associated with high patient satisfaction. Pain-reduction findings were mixed, though several studies reported meaningful improvements, particularly among highly anxious patients. Many participants expressed interest in using VR again, and some indicated they would pay for its use. Compliance outcomes varied, with one pediatric study noting decreased compliance, while others reported improved willingness to undergo procedures and shorter procedure times. Overall, VR was well received and shows promise for enhancing patient experiences in dermatology by addressing both psychological and physical discomfort. Its potential applications may extend into psychodermatology, especially for conditions influenced by psychological factors. Further research is needed to clarify cost considerations, patient preferences, and feasibility in routine clinical practice.

Background

Chronic hand eczema (CHE) is a persistent, recurrent condition that significantly impairs quality of life (QoL) and daily functioning. Limited data exists on the lived experience of U.S. CHE patients.

Objective

To assess the QoL impact of CHE symptoms in U.S. adult patients.

Methods

A cross-sectional, electronic survey was developed and distributed by the National Eczema Association to U.S. residents with self-reported eczema diagnoses. Survey topics included demographics, symptoms, treatments, and QoL impacts. Comparisons were made between those with clear/mild CHE symptoms and those with moderate/severe symptoms.

Results

Of respondents meeting inclusion criteria, 243 focused on their CHE. Common symptoms included itch (85.1%) and red, inflamed skin (78.9%). Patients with moderate/severe symptoms more often reported having a high/significant overall life impact than those who were clear/mild (40.9% vs. 8.5%, p < 0.001). Specific areas with a high/significant impact included instrumental activities of daily living (45.5%), other daily activities (36.9%), and mental health (32.9%). Despite using prescription treatments (88.5%), multiple over-the-counter (33.3% using ≥ 5) and alternative treatments (51.4% using at least one), 61.3% reported moderate to severe symptoms, and 28.0% said symptoms were minimally/not controlled.

Conclusion

CHE significantly affects QoL and daily functioning in U.S. patients. Despite use of prescription and adjunct therapies, CHE symptoms can persist and adequate symptom control is often not achieved by patients.